Navigation Links
Low micro-RNA level linked to high gene activity in AML
Date:3/6/2008

COLUMBUS, Ohio A new study suggests that a type of acute leukemia may occur in part because abnormally low levels of one small molecule result in the over-activity of genes important to the disease.

The research involved patients with acute myeloid leukemia (AML) and a gene mutation called NPM1, an alteration seen in about one-third of adult AML cases.

The findings suggest new therapeutic targets for treating the disease and should improve the understanding of AML, researchers say.

The study showed that a type of microRNA molecules important in controlling cell development and proliferation regulates two genes whose elevated activity has been linked to leukemia in humans and proven to cause leukemia in mice.

The two genes belong to the Hox family of genes, known to play a critical role in embryonic development and blood-cell development.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center, was published online Feb. 28 in the Proceedings of the National Academy of Sciences.

Weve shown that low levels of a microRNA called miR-204 are at least partly responsible for the high activity of these Hox genes, says first author Dr. Ramiro Garzon, an Ohio State cancer researcher.

If this is verified, and if we can develop a drug to modulate this microRNA, it may provide a new therapeutic intervention for these patients.

For this study, the investigators examined microRNAs levels in leukemia cells from 85 patients. They also looked for mutations in two genes in the leukemic cells: NPM1 and FLT3 (pronounced Flit-3).

The pattern of microRNA molecules present in the cells enabled the researchers to distinguish the 55 patients with mutated NPM1 genes from those with a normal gene.

Furthermore, 26 of the 85 patients had FLT3 mutations. These cases also had high levels of a microRNA called miR-155. Further experiments showed that while the high levels of miR-155 were closely associated with FLT3 mutations, they were independent of the mutation (i.e., it did not cause the high levels).

This is significant, says Garzon, an assistant professor of internal medicine. We already have drugs that target FLT3, but they are not effective by themselves. This finding suggests that if we develop a drug that targets miR-155, and combine it with a FLT3 inhibitor, we might achieve a more complete response in these patients.

Garzon and his colleagues are studying that possibility now.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-4833
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Estrogen Levels in Blood Predict Breast Cancers Return
2. Mother-daughter conflict, low serotonin level may be deadly combination
3. Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
4. Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks
5. Moderate Aerobic Fitness Levels May Cut Stroke Risk
6. Novel link between excessive nutrient levels and insulin resistance
7. Cleveland Clinic Collaborates with Google
8. ADAMS Performs Management Services for University Hospitals $600 Million Expansion/Renovation Program in Cleveland, OH
9. Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy
10. Climb to Fight Breast Cancer Offers Peaks for Every Skill Level
11. Oscar Pistorius Aims to Compete on Level Playing Field at 2008 Beijing Olympics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , ... May 06, 2016 , ... The International ... on the north end of the island close to the town famous for its ... 10th 2016. , “We continue to have an amazing experience in Greece, we ...
(Date:5/6/2016)... ... 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a ... in the Bible about helping to stop cancer. Yisrayl says there are too many suffering ... the health and science industries will pay close attention and take action. The Pastor says ...
(Date:5/6/2016)... OR (PRWEB) , ... May 06, 2016 , ... This ... but for women everywhere. The 17th annual National Women’s Health Week takes ... Office on Women’s Health are combining forces to empower women to make their health ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. co-founder, ... BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid Services ... Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross and ...
(Date:5/5/2016)... ... 2016 , ... Pivot Point Consulting achieved the ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, Depth, ... services for electronic health record (EHR) solutions from Epic Systems Corporation . ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology: